Dean Follmann

Also affiliated with National Institute of Allergy and Infectious Diseases

MedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 50 papers. Top paper: “Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial”.

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science(2022)10.1126/science.abm3425

N/A

17.7DataRank · unranked

1207 citations

David C. Montefiori, Adrian B. McDermott, Youyi Fong, David Benkeser, Weiping Deng +38 more

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

New England Journal of Medicine(2021)10.1056/nejmoa2113017

N/A

8.3DataRank · unranked

662 citations

Lindsey R. Baden, Brandon Essink, Susanne Doblecki‐Lewis, Judith M. Martin, Evan J. Anderson +33 more

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Nature Microbiology(2022)10.1038/s41564-022-01262-1

N/A

2.6DataRank · unranked

93 citations

Adrian B. McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch +56 more

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Nature Communications(2023)10.1038/s41467-023-39292-w

N/A

1.9DataRank · unranked

44 citations

Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David C. Montefiori, Allyson Mateja +19 more

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Science Translational Medicine(2023)10.1126/scitranslmed.ade9078

N/A

1.3DataRank · unranked

48 citations

David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly Janes, Weiping Deng +43 more

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Nature Medicine(2021)10.1038/s41591-021-01574-5

N/A

0.769DataRank · unranked

167 citations

Elisabeth Narayanan, Qingbo Liu, Yaroslav Tsybovsky, Kristin L. Boswell, Shilei Ding +31 more

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00263-1

N/A

0.750DataRank · unranked

24 citations

Nadine Rouphael, Stephen R. Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen +95 more

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Nature Communications(2024)10.1038/s41467-024-53727-y

N/A

0.644DataRank · unranked

21 citations

Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Daniel J Stieh +56 more

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

npj Vaccines(2023)10.1038/s41541-023-00630-0

N/A

0.557DataRank · unranked

40 citations

Youyi Fong, Holly Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule +37 more

Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial

Vaccine(2024)10.1016/j.vaccine.2024.02.071

N/A

0.457DataRank · unranked

20 citations

Youyi Fong, Nima S. Hejazi, Avi Kenny, Ying Huang, Marco Carone +3 more

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae689

N/A

0.444DataRank · unranked

8 citations

Xiaowei Wang, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Peter B. Gilbert +13 more

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Nature Communications(2024)10.1038/s41467-024-52348-9

N/A

0.428DataRank · unranked

9 citations

Youyi Fong, Jonathan Fintzi, Eric Chun‐Pu Chu, Holly Janes, Avi Kenny +37 more

Risk of COVID-19 after natural infection or vaccination

EBioMedicine(2023)10.1016/j.ebiom.2023.104799

N/A

0.396DataRank · unranked

13 citations

Matthew B. Laurens, Ying Huang, Chenchen Yu, Thomas Martin, Carina A. Rodriguez +94 more

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Nature Communications(2025)10.1038/s41467-025-55931-w

N/A

0.345DataRank · unranked

9 citations

Youyi Fong, Lauren Dang, Jonathan Fintzi, Shiyu Chen, Jing Wang +43 more

Vaccine Efficacy at a Point in Time

10.1101/2021.02.04.21251133

N/A

0.312DataRank · unranked

7 citations

Michael P. Fay, Dean Follmann

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Clinical Infectious Diseases(2024)10.1093/cid/ciae465

N/A

0.251DataRank · unranked

3 citations

Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen, Jing Wang +84 more

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad500.2470

N/A

0.208DataRank · unranked

3 citations

Xiaowei Wang, Peter B. Gilbert, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink +10 more

A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development

Biostatistics(2024)10.1093/biostatistics/kxaf018

N/A

0.208DataRank · unranked

3 citations

James Peng, Larry Han, Theis Lange, Yun Lu, Lei Nie +10 more

Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

Clinical Infectious Diseases(2025)10.1093/cid/ciaf558

N/A

0.104DataRank · unranked

1 citations

Yunda Huang, Ying Huang, Wayne Woo, Alice McGarry, Germán Áñez +37 more

Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial

iScience(2025)10.1016/j.isci.2025.113660

N/A

0.104DataRank · unranked

1 citations

Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Yiwen Lu +61 more

Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

Malaria Journal(2023)10.1186/s12936-023-04802-0

N/A

0.104DataRank · unranked

1 citations

Viviane Callier, Biraj Shrestha, Sudhaunshu Joshi, Ankit Dwivedi, Joana C. Silva +4 more

Long-term safety and efficacy of COVE study open-label and booster phases

Research Square(2024)10.21203/rs.3.rs-3900939/v1

N/A

0DataRank · unranked

0 citations

Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout +19 more

Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)

UNC Libraries(2024)10.17615/qngy-0518

N/A

0DataRank · unranked

0 citations

Yunyun Jiang, Helen W. Boucher, Paterson D.L., van Duin D., Dean Follmann +13 more

A Surrogate Endpoint Based Provisional Approval Causal Roadmap

arXiv (Cornell University)(2024)10.48550/arxiv.2407.06350

N/A

0DataRank · unranked

0 citations

James Peng, Larry Han, Theis Lange, Yun Lu, Lei Nie +10 more

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

UNC Libraries(2024)10.17615/18qe-2h49

N/A

0DataRank · unranked

0 citations

Fichtenbaum C.J, Youyi Fong, Isabel Reeder, Gilbert P.B., Spyros A. Kalams +34 more

Assessing treatment efficacy for interval-censored endpoints using multistate semi-Markov models fit to multiple data streams

Biostatistics(2024)10.1093/biostatistics/kxaf038

N/A

0DataRank · unranked

0 citations

Chengcai Liang, Allyson Mateja, Dean Follmann, Meagan P. O’Brien, Chenguang Wang +2 more

Assessing treatment efficacy for interval-censored endpoints using multistate semi-Markov models fit to multiple data streams

arXiv (Cornell University)(2025)10.48550/arxiv.2501.14097

N/A

0DataRank · unranked

0 citations

Chengcai Liang, Allyson Mateja, Dean Follmann, Meagan P. O’Brien, Chenguang Wang +2 more

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

Vaccine(2025)10.1016/j.vaccine.2025.127718

N/A

0DataRank · unranked

0 citations

Daniel S. Graciaa, Bo Zhang, Nadine Rouphael, Angela R Branche, Thomas Martin +13 more

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf572

N/A

0DataRank · unranked

0 citations

Lauren Dang, Eric Chun‐Pu Chu, Jonathan Fintzi, Holly Janes, Peter B. Gilbert +13 more

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Nature Communications(2024)10.1038/s41467-024-46536-w

N/A

0DataRank · unranked

12 citations

Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson +45 more

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Clinical Trials(2020)10.1177/1740774520939938

N/A

0DataRank · unranked

4 citations

Dean Follmann, Jing Wang, Franz Koenig, Lisa L. Korn, Christian Schoergenhofer +10 more

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

medRxiv(2020)10.1101/2020.12.14.20248137

N/A

0DataRank · unranked

25 citations

Jonathan Fintzi, Michael P. Fay, Holly Janes, Lindsey R. Baden, Hana M. El Sahly +25 more

Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis

Science Translational Medicine(2021)10.1126/scitranslmed.abd7618

N/A

0DataRank · unranked

47 citations

Veronique de Jager, Ray Y. Chen, Lori E. Dodd, Praveen Paripati, Laura E. Via +19 more

Assessing vaccine durability in randomized trials following placebo crossover

Statistics in Medicine(2021)10.1002/sim.9001

N/A

0DataRank · unranked

0 citations

Dean Follmann, Jonathan Fintzi

Vaccine efficacy at a point in time

Biostatistics(2022)10.1093/biostatistics/kxac008

N/A

0DataRank · unranked

12 citations

Michael P. Fay, Dean Follmann

Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial

medRxiv(2022)10.1101/2022.06.22.22276362

N/A

0DataRank · unranked

15 citations

Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo +35 more

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial

medRxiv(2022)10.1101/2022.04.18.22271936

N/A

0DataRank · unranked

14 citations

Holly Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks +8 more

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial

medRxiv(2022)10.1101/2022.04.06.22272763

N/A

0DataRank · unranked

12 citations

Adrian B. McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch +56 more

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Nature Communications(2023)10.1038/s41467-022-35768-3

N/A

0DataRank · unranked

102 citations

Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo +35 more

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Viruses(2023)10.3390/v15102029

N/A

0DataRank · unranked

17 citations

Nima S. Hejazi, Bryan S. Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori +38 more

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial

International Journal of Infectious Diseases(2023)10.1016/j.ijid.2023.09.012

N/A

0DataRank · unranked

14 citations

Xiaoying Shen, Lindsay N. Carpp, David Benkeser, Dean Follmann, Holly Janes +8 more

Early Discontinuation of Antibiotics in Patients Admitted With Clinically Suspected Serious Infection but Negative Cultures: Retrospective Cohort Study of Practice Patterns and Outcomes at 111 US Hospitals

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad286

N/A

0DataRank · unranked

3 citations

Sarah Warner, Chanu Rhee, Michael Klompas, Dean Follmann, Bruce Swihart +3 more

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad069

N/A

0DataRank · unranked

10 citations

Holly Janes, Eric Chun‐Pu Chu, Lakshmi Jayashankar, Christos J. Petropoulos, Leonid Serebryannyy +19 more

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Research Square(2023)10.21203/rs.3.rs-2743022/v1

N/A

0DataRank · unranked

0 citations

Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson +38 more

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

UNC Libraries(2023)10.17615/gg43-ax44

N/A

0DataRank · unranked

0 citations

David Benkeser, Baden L.R., Holly Janes, David C. Montefiori, Isa F. +19 more

Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

Research Square(2023)10.21203/rs.3.rs-3370731/v1

N/A

0DataRank · unranked

0 citations

Viviane Callier, Biraj Shrestha, Sudhaunshu Joshi, Ankit Dwivedi, Joana C. Silva +4 more

A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

UNC Libraries(2023)10.17615/wz35-3h79

N/A

0DataRank · unranked

0 citations

Michael P. Fay, Dean Follmann, Deborah Donnell, James G. Kublin, Myron S. Cohen +24 more

Immune correlates analysis using vaccinees from test negative designs

Biostatistics(2020)10.1093/biostatistics/kxaa037

N/A

0DataRank · unranked

9 citations

Lori E. Dodd, Dean Follmann

Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine

Clinical Infectious Diseases(2024)10.1093/cid/ciae081

N/A

0DataRank · unranked

10 citations

Allyson Mateja, Michael P. Fay, Craig A. Magaret, Yunda Huang, Youyi Fong +8 more

Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae632

N/A

0DataRank · unranked

2 citations

Irina Maljkovic Berry, Viviane Callier, Scott M. Anthony, Krystle Hensley, Jens H. Kuhn +10 more